For the year, the company reported that its loss widened to $167.4 million, or $2.78 per share. Cullinan Therapeutics shares have fallen 31% since the beginning of the year. The stock has declined ...

Initially an EV-focused brand, Zeekrwillo introduces its first PHEV model with the flagship SUV 9X Grand, which is scheduled ...

Net loss attributable to Cullinan was $47.6 million for the fourth quarter of 2024, compared to $23.8 million for the same period in 2023, and $167.4 million for the full year 2024, compared to $ ...

Charles Schwab Investment Management Inc. lifted its stake in Cullinan Therapeutics by 14.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,959 shares of the ...

The pandemic has underscored a universal truth: experiences often hold more value than mere possessions. Enter ...

Advertisement Article continues below this ad For the year, the company reported that its loss widened to $167.4 million, or $2.78 per share. Cullinan Therapeutics shares have fallen 31% since the ...